Categories

12-Dec-2019

Dr James Garner discusses GBM AGILE study with Boardroom Media

Our CEO, Dr James Garner sat down with Boardroom Media to discuss Kazia joining the GBM AGILE international phase II / III study in glioblastoma with its lead program, GDC-0084.

28-Nov-2019

Dr James Garner discusses GDC-0084 interim efficacy data with Pitt Street Research

Our Chief Executive Officer, Dr James Garner, sat down with Stuart Roberts of Pitt Street Research in Sydney to discuss the company’s recent announcement of positive interim efficacy data from its phase II trial of GDC-0084 in glioblastoma.

06-Sep-2019

Dr James Garner presents at the 2019 Gold Coast Investment Showcase

Our CEO, Dr James Garner recently presented an overview of the company as a guest speaker at the 2019 Gold Coast Investment Showcase.

22-Aug-2019

Dr James Garner featured in The Australian Financial Review

Our Chief Executive Officer Dr James Garner was featured in a recent article in The Australian Financial Review on the new breed of biotechnology companies.

27-Jun-2019

Dr James Garner provides comprehensive GDC-0084 update to Morgans

Our CEO, Dr James Garner recently sat down with Morgans Senior Analyst Scott Power to provide a comprehensive update on our ongoing trials for our lead candidate, GDC-0084.

26-Jun-2019

Media coverage of DIPG researcher, Professor Matt Dun for World Brain Tumour Day

Professor Matt Dun was interviewed across leading broadcast and print media about his research into DIPG, a rare but aggressive form of childhood brain cancer.

11-Jun-2019

World Brain Tumour Day: Enhancing awareness of the devastating childhood brain cancer, DIPG

Dr Matt Dun, a leading cancer researcher, discusses his research into Diffuse Intrinsic Pontine Glioma (DIPG) and GDC-0084.

28-May-2019

Dr James Garner discusses ground-breaking Alliance study with Boardroom Media

Our CEO, Dr James Garner sat down with Boardroom Media in Sydney to discuss Kazia’s participation in the ground-breaking study with the US National Cancer Institute-backed Alliance for Clinical Trials in Oncology for the treatment of cancer that has spread to the brain.

08-May-2019

Kazia calls for greater awareness of one of the deadliest women’s cancers worldwide

This World Ovarian Cancer Day, Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of one of the deadliest women’s cancers worldwide.

02-Apr-2019

Proactive Investors speaks with Kazia CEO Dr James Garner

Our CEO, Dr James Garner sat down with Karen Tan from Proactive Investors in Sydney to discuss the presentation of new data from the company’s Cantrixil trial in ovarian cancer at the American Association of Cancer Research (AACR) 2019 Annual Meeting on April 1.

11-Jan-2019

Proactive Investors speaks with Kazia CEO Dr James Garner

Our CEO, Dr James Garner sat down with Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco last week to discuss the multiple data readouts rapidly approaching for our GDC-0084 and Cantrixil clinical trial programs.

31-Oct-2018

Morgans interview with Kazia CEO Dr James Garner

Kazia Therapeutics CEO Dr James Garner was interviewed recently by Morgans Senior Analyst Scott Power about Kazia’s upcoming milestones and clinical trials.

24-Oct-2018

Potential glioblastoma therapy GDC-0084 presented to Finance News Network audience

Kazia Therapeutics CEO Dr James Garner was a key speaker at a Finance News Network event in Sydney last week.

25-Jul-2018

Sydney Shareholder Information Session July 2018

Kazia Therapeutics hosted briefing sessions for shareholders in Sydney and Melbourne this month.

11-Jul-2018

What makes our cancer therapies different

Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2018 Gold Coast Investment Showcase.

02-Jul-2018

Cantrixil phase 1 clinical study: Dr James Garner discusses the interim data

Kazia Therapeutics recently released preliminary data from its phase 1 clinical study of Cantrixil, a potential new treatment for recurrent ovarian cancer.

08-May-2018

Trials start on new treatment for ovarian cancer, the silent killer in Australia

A breakthrough new treatment for ovarian cancer that aims to stop the disease returning by killing off the cancer’s stem cells is undergoing safety trials in Australia.

03-May-2018

Meet our Scientific Advisory Board

Kazia was delighted recently to have the members of our Scientific Advisory Board gather in Sydney. We spent time working through details of our clinical trials for GDC-0084, our potential brain cancer therapeutic, and Cantrixil, our drug in development for ovarian cancer. Stuart Roberts, Senior Analyst at NDF Research took the opportunity to conduct wide-ranging interviews with each of the SAB members, which provide rich insights into their work. 

29-Mar-2018

Why GDC-0084 for glioblastoma: Q&A with Kazia CEO Dr James Garner

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing its lead therapeutic program, GDC-0084, for the deadly brain cancer, glioblastoma multiforme (GBM).

29-Mar-2018

GDC-0084 and glioblastoma multiforme

Kazia Therapeutics (ASX: KZA, NASDAQ: KZIA) is developing a new therapy called GDC-0084 to treat the rare and deadly brain cancer, glioblastoma multiforme (GBM).